Trevi Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Trevi Therapeutics, Inc. (TRVI) on March 22, 2021, covering events occurring on March 18, 2021. The company is a biopharmaceutical firm incorporated in Delaware and listed on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
- Departure of CFO: Christopher Seiter notified the Company of his resignation as Chief Financial Officer, effective April 2, 2021.
- Appointment of Principal Financial Officer: Upon Mr. Seiter's departure, Jennifer Good, the Company's President and Chief Executive Officer, will assume the role of principal financial officer.
Management Commentary and Risks
The filing details the background of Jennifer Good, noting her role as co-founder since March 2011 and her prior experience as CEO and CFO at Penwest Pharmaceuticals Co. She is a Certified Public Accountant (license currently inactive) and has served on the boards of Rhythm Pharmaceuticals and the Friedreich's Ataxia Research Alliance. No specific risks, contingencies, or unusual items were disclosed in this report.
Investor Verification Checklist
- Confirm the effective date of the CFO transition (April 2, 2021).
- Verify the interim financial reporting structure under the new principal financial officer.
- Review subsequent filings for the appointment of a permanent Chief Financial Officer.